Mode
Text Size
Log in / Sign up
Phase 3 N=1,923 Randomized Prevention

A Study of SARS CoV-2 Infection and Potential Transmission in Individuals Immunized With Moderna COVID-19 Vaccine

SARS-CoV-2 Infection

Enrolled (actual)
1,923
Serious AEs
Results posted
Jul 2023
Primary outcome: Primary: Efficacy of Moderna COVID-19 Vaccine Against SARS-CoV-2 Infection — 12.2; 31.8; 89.6 events per 100 person years

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
Moderna COVID-19 Vaccine (Biological)
Age
Adult · 18+ yrs
Sex
All
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Primary completion
Dec 2021

Outcome Measures

OutcomeResultp-value
PRIMARY
Efficacy of Moderna COVID-19 Vaccine Against SARS-CoV-2 Infection
12.2; 31.8; 89.6
PRIMARY
Effect of Moderna COVID-19 Vaccine on Mean Peak Nasal Viral Load
25.8; 20.2; 22.3; 26.3; 20.7; 22.8
PRIMARY
Effect of Moderna COVID-19 Vaccine on Median Peak Nasal Viral Load
23.9; 19.6; 21.0; 24.3; 20.0; 21.3
SECONDARY
Efficacy of Moderna COVID-19 Vaccine Against COVID-19 Disease Confirmed by PCR Test and Symptoms
SECONDARY
Efficacy of Moderna COVID-19 Vaccine Against SARS-CoV-2 Infection Regardless of Baseline Negativity
11.7; 28.3; 76.0
SECONDARY
Impact of Moderna COVID-19 Vaccine on Secondary Transmission of SARS-CoV-2 Infection
SECONDARY
Efficacy of Moderna COVID-19 Vaccine to Prevent Serologically Confirmed SARS-CoV-2 Infection
SECONDARY
Efficacy of Moderna COVID-19 Vaccine Against COVID-19 Disease Confirmed by PCR Test and Symptoms
SECONDARY
Effect of Moderna COVID-19 Vaccine on Magnitude of Viral Load Over Time
SECONDARY
Efficacy of Moderna Vaccine Regardless of Baseline Serostatus (SARS-CoV-2 Infection by PCR)
SECONDARY
Effect of Moderna Vaccine on Viral Load Regardless of Baseline Serostatus (Viral Load)
SECONDARY
Effect of Moderna Vaccine on Secondary Status Regardless of Baseline Serostatus (Secondary Transmission Events)
SECONDARY
Immunogenicity of Moderna COVID-19 Vaccine
SECONDARY
Immune Responses as Correlates of Risk of SARS-CoV-2 Acquisition, Viral Load, Secondary Infection, and COVID-19 Disease
SECONDARY
Efficacy of Moderna COVID-19 Vaccine Against Asymptomatic SARS-CoV-2 Infection
SECONDARY
Efficacy of Moderna COVID-19 Vaccine Against SARS-CoV-2 Infection and COVID-19 Disease
SECONDARY
Effect of Moderna COVID-19 Vaccine on Viral Load
SECONDARY
Effect of Moderna COVID-19 Vaccine on Secondary Transmission

Summary

The purpose of this study is to assess SARS CoV-2 infection, viral shedding, and subsequent potential transmission in individuals immunized with the Moderna COVID-19 vaccine.

Eligibility Criteria

Inclusion criteria for Main cohort, Vaccine Declined Group General and Demographic Criteria

  • Age of 18 through 29 years.
  • Ability and willingness to provide informed consent.
  • Prefers not to receive COVID-19 vaccine.
  • Willingness to be followed for the planned duration of the study.
  • Assessment of understanding: volunteer demonstrates understanding of this study; completes a questionnaire with demonstration of understanding of all questionnaire items answered incorrectly.
  • Access to device and internet for completion of study procedures.

Exclusion criteria for Main cohort, Vaccine Declined Group

  • Prior administration of a coronavirus (SARS-CoV-2, SARS-CoV, MERS-CoV) vaccine or current/planned simultaneous participation in another interventional study to prevent or treat COVID-19 (participation in studies of other investigational research agents allowed).
  • Any medical, psychiatric, occupational, or other condition that, in the judgment of the investigator, would interfere with, or serve as a contraindication to, protocol adherence, or a volunteer's ability to give informed consent.

Inclusion criteria for Prospective Close Contact (PCC) cohort

  • Age of 18 years or older, at the time of signing the informed consent.
  • Willing and able to provide informed consent.
  • Expected to be in frequent close physical proximity with Main Cohort participant during the study.
  • Willing to share results of SARS-CoV-2 testing.
  • Access to device and internet for completion of study procedures

Inclusion criteria for Case-ascertained Close Contact (CACC) cohort

  • Age of 18 years or older, at the time of signing the informed consent.
  • Willing and able to provide informed consent.
  • Access to device and internet for completion of study procedures.
  • Willing to share results of SARS-CoV-2 testing.
  • Had close contact with Main Cohort participant with known PCR-confirmed SARS-CoV-2 infection (eg, index case). Close contacts will have had exposure to the index participant, generally within 72 hours of an index diagnosis, and may include individuals that meet any of the following guidelines:

Prolonged close physical proximity with Main Cohort participant within a residence/vehicle/enclosed space without maintaining social distance,

Medical staff, first responders, or other care persons who cared for the index case without appropriate personal protective equipment.

Further information on the definition of close contact can be found in the CoVPN 3006 Study Specific Procedures (SSP).

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04811664). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search